Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
- Autores
- Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; Castellsagué, Xavier; Alkaff, Sharifa Ezat; Felder, Tamika; Hammouda, Doudja; Konno, Ryo; Lopes, Gilberto; Mugisha, Emmanuel; Murillo, Rául; Scarinci, Isabel C.; Stanley, Margaret; Tsu, Vivien; Wheeler, Cosette M.; Adewole, Isaac Folorunso; de Sanjosé, Silvia
- Año de publicación
- 2017
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
Fil: Arrossi, Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional del Cancer; Argentina
Fil: Temin, Sarah. American Society of Clinical Oncology; Estados Unidos
Fil: Garland, Suzanne. University of Melbourne; Australia
Fil: O'Neal Eckert, Linda. University of Washington; Estados Unidos
Fil: Bhatla, Neerja. PATH; Estados Unidos
Fil: Castellsagué, Xavier. L’Hospitalet de Llobregat; España
Fil: Alkaff, Sharifa Ezat. Universiti Kebangsaan; Malasia
Fil: Felder, Tamika. Cervivor; Estados Unidos
Fil: Hammouda, Doudja. Institut National de Santé Publique; Argelia
Fil: Konno, Ryo. Jichi Medical University; Japón
Fil: Lopes, Gilberto. Sylvester Comprehensive Cancer Center; Estados Unidos
Fil: Mugisha, Emmanuel. PATH; Uganda
Fil: Murillo, Rául. International Agency for Research on Cance; Francia
Fil: Scarinci, Isabel C.. University of Alabama at Birmingahm; Estados Unidos
Fil: Stanley, Margaret. University of Cambridge; Reino Unido
Fil: Tsu, Vivien. PATH; Estados Unidos
Fil: Wheeler, Cosette M.. University of New Mexico; Estados Unidos
Fil: Adewole, Isaac Folorunso. Ministry of Health; Nigeria
Fil: de Sanjosé, Silvia. L’Hospitalet de Llobregat; España - Materia
-
Cervical cancer
HPV vaccination - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/77736
Ver los metadatos del registro completo
id |
CONICETDig_5ce315b794bdcb71b381756bd8ff3975 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/77736 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified GuidelineArrossi, SilvinaTemin, SarahGarland, SuzanneO'Neal Eckert, LindaBhatla, NeerjaCastellsagué, XavierAlkaff, Sharifa EzatFelder, TamikaHammouda, DoudjaKonno, RyoLopes, GilbertoMugisha, EmmanuelMurillo, RáulScarinci, Isabel C.Stanley, MargaretTsu, VivienWheeler, Cosette M.Adewole, Isaac Folorunsode Sanjosé, SilviaCervical cancerHPV vaccinationhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.Fil: Arrossi, Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional del Cancer; ArgentinaFil: Temin, Sarah. American Society of Clinical Oncology; Estados UnidosFil: Garland, Suzanne. University of Melbourne; AustraliaFil: O'Neal Eckert, Linda. University of Washington; Estados UnidosFil: Bhatla, Neerja. PATH; Estados UnidosFil: Castellsagué, Xavier. L’Hospitalet de Llobregat; EspañaFil: Alkaff, Sharifa Ezat. Universiti Kebangsaan; MalasiaFil: Felder, Tamika. Cervivor; Estados UnidosFil: Hammouda, Doudja. Institut National de Santé Publique; ArgeliaFil: Konno, Ryo. Jichi Medical University; JapónFil: Lopes, Gilberto. Sylvester Comprehensive Cancer Center; Estados UnidosFil: Mugisha, Emmanuel. PATH; UgandaFil: Murillo, Rául. International Agency for Research on Cance; FranciaFil: Scarinci, Isabel C.. University of Alabama at Birmingahm; Estados UnidosFil: Stanley, Margaret. University of Cambridge; Reino UnidoFil: Tsu, Vivien. PATH; Estados UnidosFil: Wheeler, Cosette M.. University of New Mexico; Estados UnidosFil: Adewole, Isaac Folorunso. Ministry of Health; NigeriaFil: de Sanjosé, Silvia. L’Hospitalet de Llobregat; EspañaAmerican Society of Clinical Oncology2017-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/77736Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; et al.; Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline; American Society of Clinical Oncology; Journal of Global Oncology; 3; 5; 10-2017; 611-6342378-9506CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1200/JGO.2016.008151info:eu-repo/semantics/altIdentifier/url/https://ascopubs.org/doi/10.1200/JGO.2016.008151info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:59:04Zoai:ri.conicet.gov.ar:11336/77736instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:59:04.877CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
title |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
spellingShingle |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline Arrossi, Silvina Cervical cancer HPV vaccination |
title_short |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
title_full |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
title_fullStr |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
title_full_unstemmed |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
title_sort |
Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline |
dc.creator.none.fl_str_mv |
Arrossi, Silvina Temin, Sarah Garland, Suzanne O'Neal Eckert, Linda Bhatla, Neerja Castellsagué, Xavier Alkaff, Sharifa Ezat Felder, Tamika Hammouda, Doudja Konno, Ryo Lopes, Gilberto Mugisha, Emmanuel Murillo, Rául Scarinci, Isabel C. Stanley, Margaret Tsu, Vivien Wheeler, Cosette M. Adewole, Isaac Folorunso de Sanjosé, Silvia |
author |
Arrossi, Silvina |
author_facet |
Arrossi, Silvina Temin, Sarah Garland, Suzanne O'Neal Eckert, Linda Bhatla, Neerja Castellsagué, Xavier Alkaff, Sharifa Ezat Felder, Tamika Hammouda, Doudja Konno, Ryo Lopes, Gilberto Mugisha, Emmanuel Murillo, Rául Scarinci, Isabel C. Stanley, Margaret Tsu, Vivien Wheeler, Cosette M. Adewole, Isaac Folorunso de Sanjosé, Silvia |
author_role |
author |
author2 |
Temin, Sarah Garland, Suzanne O'Neal Eckert, Linda Bhatla, Neerja Castellsagué, Xavier Alkaff, Sharifa Ezat Felder, Tamika Hammouda, Doudja Konno, Ryo Lopes, Gilberto Mugisha, Emmanuel Murillo, Rául Scarinci, Isabel C. Stanley, Margaret Tsu, Vivien Wheeler, Cosette M. Adewole, Isaac Folorunso de Sanjosé, Silvia |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
Cervical cancer HPV vaccination |
topic |
Cervical cancer HPV vaccination |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines. Fil: Arrossi, Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional del Cancer; Argentina Fil: Temin, Sarah. American Society of Clinical Oncology; Estados Unidos Fil: Garland, Suzanne. University of Melbourne; Australia Fil: O'Neal Eckert, Linda. University of Washington; Estados Unidos Fil: Bhatla, Neerja. PATH; Estados Unidos Fil: Castellsagué, Xavier. L’Hospitalet de Llobregat; España Fil: Alkaff, Sharifa Ezat. Universiti Kebangsaan; Malasia Fil: Felder, Tamika. Cervivor; Estados Unidos Fil: Hammouda, Doudja. Institut National de Santé Publique; Argelia Fil: Konno, Ryo. Jichi Medical University; Japón Fil: Lopes, Gilberto. Sylvester Comprehensive Cancer Center; Estados Unidos Fil: Mugisha, Emmanuel. PATH; Uganda Fil: Murillo, Rául. International Agency for Research on Cance; Francia Fil: Scarinci, Isabel C.. University of Alabama at Birmingahm; Estados Unidos Fil: Stanley, Margaret. University of Cambridge; Reino Unido Fil: Tsu, Vivien. PATH; Estados Unidos Fil: Wheeler, Cosette M.. University of New Mexico; Estados Unidos Fil: Adewole, Isaac Folorunso. Ministry of Health; Nigeria Fil: de Sanjosé, Silvia. L’Hospitalet de Llobregat; España |
description |
Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/77736 Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; et al.; Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline; American Society of Clinical Oncology; Journal of Global Oncology; 3; 5; 10-2017; 611-634 2378-9506 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/77736 |
identifier_str_mv |
Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; et al.; Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline; American Society of Clinical Oncology; Journal of Global Oncology; 3; 5; 10-2017; 611-634 2378-9506 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1200/JGO.2016.008151 info:eu-repo/semantics/altIdentifier/url/https://ascopubs.org/doi/10.1200/JGO.2016.008151 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
American Society of Clinical Oncology |
publisher.none.fl_str_mv |
American Society of Clinical Oncology |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1846083131795308544 |
score |
13.22299 |